Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
East Orange, NJ
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
East Orange, NJ
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
New York, NY
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
New York, NY
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
Charleston, SC
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
Seattle, WA
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
Clinical Research Facility
mi
from
Madison, WI
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
mi
from
Washington, D.C.,
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated:  10/11/2017
mi
from
Edmonton,
Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Status: Enrolling
Updated: 10/11/2017
mi
from
Edmonton,
Click here to add this to my saved trials
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer
Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate
Status: Enrolling
Updated:  10/11/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer
Phase II Study Evaluating Pomegranate Juice In Patients With Recurrent Adenocarcinoma Of The Prostate
Status: Enrolling
Updated: 10/11/2017
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  10/13/2017
Stanford University
mi
from
Stanford, CA
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 10/13/2017
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
UAB Comprehensive Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Arizona Center for Cancer Care - Peoria
mi
from
Peoria, AZ
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Arizona Oncology Services Foundation
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Kaiser Permanente - Division of Research - Oakland
mi
from
Oakland, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Kaiser Permanente - Division of Research - Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Rohnert Park Cancer Center
mi
from
Rohnert Park, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Rohnert Park Cancer Center
mi
from
Rohnert Park, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Kaiser Permanente Medical Center - Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Kaiser Permanente Santa Clara Medical Center
mi
from
Santa Clara, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Kaiser Permanente Santa Clara Medical Center
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Kaiser Permanente Medical Center - South San Francisco
mi
from
South San Francisco, CA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Kaiser Permanente Medical Center - South San Francisco
mi
from
South San Francisco, CA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Urology Center of Colorado
mi
from
Denver, CO
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Urology Center of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Emory Crawford Long Hospital
mi
from
Atlanta, GA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Emory Crawford Long Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Queen's Cancer Institute at Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Boston University Cancer Research Center
mi
from
Boston, MA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Rosenfeld Cancer Center at Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Rothman Specialty Hospital
mi
from
Bensalem, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Rothman Specialty Hospital
mi
from
Bensalem, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Fox Chase Cancer Center Buckingham
mi
from
Furlong, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Fox Chase Cancer Center Buckingham
mi
from
Furlong, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Academic Urology Prostate Center
mi
from
King of Prussia, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Academic Urology Prostate Center
mi
from
King of Prussia, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Hollings Cancer Center at Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Columbia-Saint Mary's Cancer Care Center
mi
from
Milwaukee, WI
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Columbia-Saint Mary's Cancer Care Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Natalie Warren Bryant Cancer Center at St. Francis Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Fox Chase Cancer Center - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated:  10/16/2017
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Radiation Therapy in Treating Patients With Prostate Cancer
A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer
Status: Enrolling
Updated: 10/16/2017
Cross Cancer Institute at University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
Multiparametric MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Cancer (MAVERICK)
Status: Enrolling
Updated:  10/17/2017
Hunter Holmes McGuire Veteran Affairs Medical Center
mi
from
Richmond, VA
MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca
Multiparametric MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Cancer (MAVERICK)
Status: Enrolling
Updated: 10/17/2017
Hunter Holmes McGuire Veteran Affairs Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
A Physical Activity Behavior Change Guide for Prostate Cancer Patients (iTRAIN Study)
Status: Enrolling
Updated:  10/17/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy
A Physical Activity Behavior Change Guide for Prostate Cancer Patients (iTRAIN Study)
Status: Enrolling
Updated: 10/17/2017
OHSU Knight Cancer Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Study of Weekly Intravenous 1,25 Dihydroxycholecelciferol (Calcitriol) + Dexamethasone in Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  10/17/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Phase II Study of Weekly Intravenous 1,25 Dihydroxycholecelciferol (Calcitriol) + Dexamethasone in Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 10/17/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/18/2017
National Cancer Institute
mi
from
Bethesda, MD
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/18/2017
National Cancer Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/18/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/18/2017
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated:  10/18/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
A Phase II Study of Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Enrolling
Updated: 10/18/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
Status: Enrolling
Updated:  10/18/2017
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160
Status: Enrolling
Updated: 10/18/2017
University of Alabama Hematology Oncology Clinic at Medical West
mi
from
Birmingham, AL
Click here to add this to my saved trials